8-chloro-N'-(3-(pyridin-4-yl)propanoyl)dibenzo[b,f][1,4]oxazepine-10(11H)-carbohydrazide

Catalog No. :
ACBOUX218
CAS No. :
146033-03-6
Molecular Formula :
C22H19ClN4O3
Molecular Weight :
422.87

IUPAC Name:8-chloro-N'-(3-(pyridin-4-yl)propanoyl)dibenzo[b,f][1,4]oxazepine-10(11H)-carbohydrazide

8-chloro-N'-(3-(pyridin-4-yl)propanoyl)dibenzo[b,f][1,4]oxazepine-10(11H)-carbohydrazide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name8-chloro-N'-(3-(pyridin-4-yl)propanoyl)dibenzo[b,f][1,4]oxazepine-10(11H)-carbohydrazide
IUPAC Name8-chloro-N'-(3-(pyridin-4-yl)propanoyl)dibenzo[b,f][1,4]oxazepine-10(11H)-carbohydrazide
Molecular FormulaC22H19ClN4O3
Molecular Weight422.87
SMILESO=C(CCC1=CC=NC=C1)NNC(=O)N1CC2=CC=CC=C2OC2=C1C=C(Cl)C=C2
InChI KeyXDJPQOUDGROSEU-UHFFFAOYSA-N
SynonymDibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-[1-oxo-3-(4-pyridinyl)propyl]hydrazide;SC 51089 free base
CAS No.146033-03-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACBOUX218 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACANRB395 route compound structure diagram
    ACANRB3956318-43-0 In Stock
  4. Then
  5. ACBOUX218 route product structure diagram
    ACBOUX218146033-03-6
Inquiry

2. ACBOUX218 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBOUX218 route product structure diagram
    ACBOUX218146033-03-6
Inquiry

Comments (0)